ArticleWorld journal of clinical cases2022
Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report.
Xian Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.